Graft Versus Host Disease News and Research

Latest Graft Versus Host Disease News and Research

Roche's high-throughput sequencing technology used for high-resolution HLA genotyping

A study published this month in the journal Tissue Antigens reports that researchers at Roche Molecular Systems in Pleasanton, CA have used high-throughput sequencing technology from 454 Life Sciences, a Roche Company, to carry out high-resolution human leukocyte antigen (HLA) genotyping in research samples.

27 Oct 2009

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated enrollment in its confirmatory Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial evaluating orBec(®) for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD).

15 Oct 2009

SCID infants who receive early bone marrow transplants are likely to have fewer complications

Mention the words "bubble boy" and many will recall David Vetter, the kid with big eyes and a thick thatch of dark hair who died 25 years ago after spending almost the entire 12 years of his life in a germ-free, plastic bubble. David was born with severe combined immune deficiency, or SCID, a condition that robbed him of an immune system.

14 Oct 2009

Private cord blood banking can treat medical conditions but is expensive

Private cord blood banking is not cost-effective because it costs an additional $1,374,246 per life-year gained, according to a new analysis by UCSF researchers. The research team also concluded that private cord blood banking is cost-effective only for families with a child with a very high likelihood of needing a stem cell transplant.

23 Sep 2009

Preliminary results of Phase III Gvhd trials announced by Osiris Therapeutics

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced preliminary results for two phase III trials evaluating Prochymal for the treatment of acute graft versus host disease (GvHD). GvHD, the most common complication of bone marrow transplantation, is a life-threatening disease for which there is currently no approved treatment. Prochymal showed significant improvements in response rates in difficult-to-treat liver and gastrointestinal GvHD, however neither trial reached its primary endpoint.

8 Sep 2009

Combined therapy for acute leukemia shows promising results

Two of the most powerful approaches to cancer treatment -- a stem cell transplant and an immune system-stimulating vaccine -- appear to reinforce each other in patients with an aggressive, hard-to-control form of leukemia, Dana-Farber Cancer Institute scientists have found.

25 Aug 2009

Gentium reports results from phase 3 trial of defibrotide for severe veno-occlusive disease

Gentium S.p.A. has announced top-line results from a historically controlled, multicenter, open label, Phase III trial designed to evaluate the safety and efficacy of 25 mg/kg/day of Defibrotide for the treatment of severe veno-occlusive disease (sVOD) in hematopoietic stem cell transplant (SCT) patients.

19 Aug 2009

Type 1 diabetes patients sought for UT Southwestern clinical drug trial

UT Southwestern Medical Center researchers are recruiting individuals newly diagnosed with type 1 diabetes for a clinical trial to gauge the effectiveness of adding an investigational stem cell product to standard insulin therapy.

3 Mar 2009

New approaches to prevent transplant rejection

To prevent the rejection of newly transplanted organs and cells, patients must take medicines that weaken their entire immune systems.

15 Feb 2009

Bone marrow transplant patients may benefit from new immune research

Bone marrow transplant (BMT) researchers at The Medical College of Wisconsin Cancer Center in Milwaukee may have found a mechanism that could preserve the leukemia-killing effects of a transplant graft, while limiting the damage donor immune cells might do to the recipient host's vital organs.

11 Feb 2009

ViroPharma reports results of trial for Maribavir in bone marrow transplant patients

ViroPharma Incorporated has announced that its Phase 3 trial evaluating maribavir used as prophylaxis in allogeneic stem cell, or bone marrow, transplant (SCT) patients did not achieve its primary endpoint.

10 Feb 2009

Effects of stem cell source and patient age on stem cell transplantation outcomes

Two studies examining the effects of stem cell source and patient age on stem cell transplantation outcomes were explored at a press conference on Sunday, December 7 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA.

8 Dec 2008

Kiadis Pharma announces positive results for ATIR in mismatched bone marrow transplantation

Biopharmaceutical company Kiadis Pharma announces that it has successfully completed treatment of the last patient on its ATIR phase I/II clinical trial.

8 Dec 2008

Bone marrow stem cells used to protect gastrointestinal tissue from autoimmune attack

Massachusetts General Hospital (MGH) investigators have found that infusions of a particular bone marrow stem cell appeared to protect gastrointestinal tissue from autoimmune attack in a mouse model.

20 Aug 2008

Potential new way to prevent graft-versus-host disease

A new University of Michigan study in mice suggests that a drug recently approved to fight cancer tumors is also able to reduce the effects of graft-versus-host disease, a common and sometimes fatal complication for people who have had bone marrow transplants.

10 Jul 2008

Adult human stem cells shown not to pose a cancer risk when implanted into different organs

A new study by UC Davis researchers provides evidence that methods using human bone marrow-derived stem cells to deliver gene therapy to cure diseases of the blood, bone marrow and certain types of cancer do not cause the development of tumors or leukemia.

6 May 2008

New interventional radiology treatment shows promise for complications from bone marrow, stem cell tranplants

The standard treatment to treat graft-versus-host disease (GVHD) after bone marrow or cord blood transplant is intravenous (IV) steroids that alter the immune response; however, it is not always effective and failure results in very high mortality.

19 Mar 2008

Umbilical cord blood transplant may confer advantages over bone marrow transplant for kids with life-threatening metabolic disorders

Children born with inherited metabolic disorders that cause organ failure and early death can be treated successfully with umbilical cord blood transplants from unrelated donors and, in some cases go on to live for many years, according to a study led by Duke University Medical Center researchers.

10 Dec 2007

Mini transplant patients' outcomes similar using related and unrelated donor cells

People who undergo nonmyeloablative stem-cell transplants, or "mini transplants," for leukemia, lymphoma and other blood cancers have comparable outcomes regardless of whether they receive tissue-matched stem cells from a related or unrelated donor, according to new findings by researchers at Fred Hutchinson Cancer Research Center.

4 Dec 2007

Sexual function affected by stem cell transplant according to long-term study

A long-term study found that a type of stem cell transplant used for patients with life-threatening diseases, such as leukemia and lymphoma, results in decreased sexual function and activity for recipients.

18 Sep 2007

Graft Versus Host Disease News and Research

Latest Graft Versus Host Disease News and Research

Roche's high-throughput sequencing technology used for high-resolution HLA genotyping

Soligenix commences enrollment in its Phase 3 Orbec clinical trial for acute GI GVHD

SCID infants who receive early bone marrow transplants are likely to have fewer complications

Private cord blood banking can treat medical conditions but is expensive

Preliminary results of Phase III Gvhd trials announced by Osiris Therapeutics

Combined therapy for acute leukemia shows promising results

Gentium reports results from phase 3 trial of defibrotide for severe veno-occlusive disease

Type 1 diabetes patients sought for UT Southwestern clinical drug trial

New approaches to prevent transplant rejection

Bone marrow transplant patients may benefit from new immune research

ViroPharma reports results of trial for Maribavir in bone marrow transplant patients

Effects of stem cell source and patient age on stem cell transplantation outcomes

Kiadis Pharma announces positive results for ATIR in mismatched bone marrow transplantation

Bone marrow stem cells used to protect gastrointestinal tissue from autoimmune attack

Potential new way to prevent graft-versus-host disease

Adult human stem cells shown not to pose a cancer risk when implanted into different organs

New interventional radiology treatment shows promise for complications from bone marrow, stem cell tranplants

Umbilical cord blood transplant may confer advantages over bone marrow transplant for kids with life-threatening metabolic disorders

Mini transplant patients' outcomes similar using related and unrelated donor cells

Sexual function affected by stem cell transplant according to long-term study

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Graft Versus Host Disease News and Research

Latest Graft Versus Host Disease News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in